hemotune AG together with ETH Zurich and Wyss Zurich received an Innosuisse grant worth CHF 580’000, to further advance hemotune’s sepsis treatment. The grant supports the development of hemotune’s magnetic blood purification that selectively removes multiple key drivers of sepsis. Sepsis is a dysregulated immune response to infection with globally 11 million deaths. Its most severe form septic shock has mortality rates of 30-50%.
hemotune’s treatment is designed to restore adequate immune function in septic shock patients and to improve their outcomes. Innosuisse, the Swiss Innovation Agency, supports innovation projects between research institutes and industry that benefit the Swiss economy and society.
We are very happy to receive this support on our journey to fight sepsis.